137 related articles for article (PubMed ID: 32512165)
21. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
22. Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.
Ratbi I; Bocciardi R; Regragui A; Ravazzolo R; Sefiani A
Clin Rheumatol; 2010 Jan; 29(1):119-21. PubMed ID: 19795179
[TBL] [Abstract][Full Text] [Related]
23. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
[TBL] [Abstract][Full Text] [Related]
24. ACVR1 gene mutation in sporadic Korean patients with fibrodysplasia ossificans progressiva.
Lee DY; Cho TJ; Lee HR; Park MS; Yoo WJ; Chung CY; Choi IH
J Korean Med Sci; 2009 Jun; 24(3):433-7. PubMed ID: 19543505
[TBL] [Abstract][Full Text] [Related]
25. Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.
Katagiri T; Tsukamoto S; Kuratani M
Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34206903
[TBL] [Abstract][Full Text] [Related]
26. ACVR1 gene mutations in four Turkish patients diagnosed as fibrodysplasia ossificans progressiva.
Eresen Yazıcıoğlu C; Karatosun V; Kızıldağ S; Ozsoylu D; Kavukçu S
Gene; 2013 Feb; 515(2):444-6. PubMed ID: 23260810
[TBL] [Abstract][Full Text] [Related]
27. Confirmation of the recurrent ACVR1 617G>A mutation in South Africans with fibrodysplasia ossificans progressiva.
Dandara C; Scott C; Urban M; Fieggen K; Arendse R; Beighton P
S Afr Med J; 2012 May; 102(7):631-3. PubMed ID: 22748444
[TBL] [Abstract][Full Text] [Related]
28. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
Aykul S; Huang L; Wang L; Das NM; Reisman S; Ray Y; Zhang Q; Rothman N; Nannuru KC; Kamat V; Brydges S; Troncone L; Johnsen L; Yu PB; Fazio S; Lees-Shepard J; Schutz K; Murphy AJ; Economides AN; Idone V; Hatsell SJ
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35511419
[TBL] [Abstract][Full Text] [Related]
29. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.
Carvalho DR; Navarro MM; Martins BJ; Coelho KE; Mello WD; Takata RI; Speck-Martins CE
Clin Genet; 2010 Feb; 77(2):171-6. PubMed ID: 19796185
[TBL] [Abstract][Full Text] [Related]
30. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
[TBL] [Abstract][Full Text] [Related]
31. The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva.
Nakajima M; Haga N; Takikawa K; Manabe N; Nishimura G; Ikegawa S
J Hum Genet; 2007; 52(5):473-475. PubMed ID: 17351709
[TBL] [Abstract][Full Text] [Related]
32. Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene.
Huang X; Roeder A; Li R; Beers J; Liu C; Zou J; Yu PB; Zheng W
Stem Cell Res; 2021 Jul; 54():102424. PubMed ID: 34139597
[TBL] [Abstract][Full Text] [Related]
33. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.
Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P
Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373
[TBL] [Abstract][Full Text] [Related]
34. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
[TBL] [Abstract][Full Text] [Related]
35. Pathogenic ACVR1
Ramachandran A; Mehić M; Wasim L; Malinova D; Gori I; Blaszczyk BK; Carvalho DM; Shore EM; Jones C; Hyvönen M; Tolar P; Hill CS
EMBO J; 2021 Jul; 40(14):e106317. PubMed ID: 34003511
[TBL] [Abstract][Full Text] [Related]
36. AAV-Mediated Targeting of the Activin A-ACVR1
Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
[TBL] [Abstract][Full Text] [Related]
37. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
38. Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting.
Nagar G; Mittal P; Gupta SRR; Pahuja M; Sanger M; Mishra R; Singh A; Singh IK
Brief Funct Genomics; 2023 Apr; 22(2):123-142. PubMed ID: 36003055
[TBL] [Abstract][Full Text] [Related]
39. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.
Allen RS; Tajer B; Shore EM; Mullins MC
Elife; 2020 Sep; 9():. PubMed ID: 32897189
[TBL] [Abstract][Full Text] [Related]
40. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
